Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MISTRAL

Financiado

Cerrado

Microbiome based stratification of individuals at risk of HIV 1 acquisition chr...

Microbiome based stratification of individuals at risk of HIV 1 acquisition chronic clinical complications antimicrobial drug resistance and unresponsiveness to therapeutic HIV 1 vaccination The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increase in deaths since 2010) and o... ver más

31/12/2025

FUNDACIO PRIVADA I...

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 5M€

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-11

SC1-BHC-14-2019: Stratified host-directed approaches...

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

FUNDACIO PRIVADA INSTITUT DE...

3.82M€ | Lider

IHU MEDITERRANEE INFECTION

N.D. | Participante

719.57K€ | Participante

HOSPITAL CLINIC DE BARCELONA

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MAARS Microbes in Allergy and Autoimmunity Related to the Skin 8M€ Cerrado

IMMEDIATE Imminent Disease Prediction and Prevention at the Environmen... 6M€ Cerrado

MITI 2 Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease... 6M€ Cerrado

MIBEst Molecular Infection Biology Estonia Research capacity buil... 797K€ Cerrado

MICAfrica Towards a North African Consortium of the Human Microbiome... 897K€ Cerrado

CPP2021-008310 Interrelación del microbioma y la inmunidad entrenada para e... 395K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2019-12-11
Fecha Fin: 2025-12-31

Líder del proyecto

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 5M€

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increase in deaths since 2010) and other regions of the world despite increasing access to antiretroviral treatment. There is emerging evidence that the human microbiome impacts some of the most important clinical aspects of HIV-1 infection, including immune disorders, chronic inflammation and accelerated aging. Work in other viral diseases and cancer immunotherapy suggest a critical role of the human microbiome also in the outcome of immune therapeutic interventions in HIV-1 infection. The MISTRAL project brings together a team of world-class HIV and microbiome researchers and SMEs with ideal complementary knowledge and expertise. This team will work to discover and validate novel gut microbiome biomarkers to inform rationally-designed, mechanistically-driven interventions on the gut microbiome to mitigate HIV-1 acquisition, systemic inflammation, chronic clinical complications, antimicrobial drug resistance, and boost the efficacy of HIV cure immunotherapies. Integrated and curated large microbiome and host datasets generated during the execution of the project will be made public through a freely accessible, specifically-dedicated web-based repository. Biomarker discoveries will be incorporated into a cloud-based software tool that will automate microbiome analyses and interpretations, thus streamlining patient stratification for clinical and research purposes. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores